<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540369</url>
  </required_header>
  <id_info>
    <org_study_id>17995</org_study_id>
    <nct_id>NCT02540369</nct_id>
  </id_info>
  <brief_title>To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.</brief_title>
  <acronym>PEGASUS</acronym>
  <official_title>PEGASUS: A Prospective obsErvational Study in Patients With Wet aGe-related Macular Degeneration or Diabetic Macular Edema to ASsess the Use of Intravitreal Aflibercept in roUtine Clinical practiceS in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the use of intravitreal aflibercept in routine clinical practice and to describe
      follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical
      practice in Canada for a study population of treatment naive patients and those who have
      received prior therapy (anti-VEGF injections, laser, steroids, etc).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2015</start_date>
  <completion_date type="Actual">January 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 25, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of visual acuity.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Treatment in na誰ve and previously treated patients for wAMD and DME.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of visual acuity.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>For the overall population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of visual acuity by number of Injections.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>In 2 sub groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Retinal thickness.</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment patterns used in routine clinical practice setting.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number of visits and examinations per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum interval between treatments.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time between injections.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections at 12 months.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve stability of disease.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections in a year to achieve stability of disease.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In previously treated subpopulation duration of previous treatments</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In previously treated subpopulation type of previous treatments.</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In previously treated subpopulation reason to switch to Eylea.</measure>
    <time_frame>At Baseline</time_frame>
    <description>Some of the reasons are recurrence of fluid, new hemorrhage - bleed, decreased vision, lack of compliance, patient request, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with no fluid determined by Optical coherence tomography (OCT).</measure>
    <time_frame>At 4 months, At 12 months</time_frame>
    <description>Absence of fluid would be determined by physician's judgment in the AMD population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of patients require adjunctive therapies.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>For Diabetic macular edema patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of adjunctive therapies required by patients</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>For Diabetic macular edema patients adjunctive therapies as focal laser, steroids, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of pigment epithelial detachment (PED) (Y/N)</measure>
    <time_frame>Baseline and at 12 months</time_frame>
    <description>For Age-related macular degeneration patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy severity (mild, moderate, severe).</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>For Diabetic macular edema patients.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2150</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>BAY86-5321- with wAMD</arm_group_label>
    <description>Patients with wet Age Related Macular Degeneration (wAMD) both na誰ve and previously treated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY86-5321 - with DME</arm_group_label>
    <description>Patients with Diabetic Macular Edema (DME) both na誰ve and previously treated patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.</description>
    <arm_group_label>BAY86-5321- with wAMD</arm_group_label>
    <arm_group_label>BAY86-5321 - with DME</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with wAMD (wet age-related macular degeneration) and DME (Diabetic macular edema)
        treated by retina specialist/ophthalmologist in selected Canadian clinical sites
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt;= 18 years of age

          -  Male or female

          -  Patients with wet AMD (wet age-related macular degeneration) or Diabetic macular edema
             (DME) who will be treated by intravitreal aflibercept according to the Canadian
             Product monograph recommendations and routine clinical practice.

          -  Decision to treat with intravitreal aflibercept prior to patient enrolment as per the
             physician's routine clinical practice.

        Exclusion Criteria:

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice.

          -  Patients currently being treated with intravitreal aflibercept. This study will only
             include patients new to intravitreal aflibercept, both na誰ve and previously treated
             with other anti-VEGF therapies.

          -  Patients who are hypersensitive to this drug, to any ingredient in the formulation, or
             to any component of the container.

          -  Patients who are hypersensitive to this drug, to any ingredient in the formulation, or
             to any component of the container.

          -  Ocular or peri-ocular infection

          -  Active intraocular inflammation

          -  Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.

          -  Any concomitant therapy with another agent to treat wet AMD or DME in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2015</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>Wet Age-related macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

